Subcutaneous siRNA against C3
Search documents
Apellis Pharmaceuticals, Inc. (APLS) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Seeking Alpha· 2026-03-02 17:57
Question-and-Answer SessionCedric FrancoisCo-Founder, President, CEO & Director Thank you, Phil, and thank you for inviting us again to this wonderful conference. So this year is a very important year for us. Last year, we went through a phase of building a good foundation for what the next phase for Apellis will be. And right now, we have three pillars in the organization with SYFOVRE. We have a durable and resilient business where we plan to continue to provide a best-in-class therapy to patients with geo ...